Patrick Reichenbach

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


12 publications

2023 | 2022 | 2021 | 2020 | 2019 | 2016 | 1997 | 1994 |
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
Tillé L., Cropp D., Charmoy M., Reichenbach P., Andreatta M., Wyss T., Bodley G., Crespo I., Nassiri S., Lourenco J. et al., 2023/10. Nature immunology, 24 (10) pp. 1645-1653. Peer-reviewed.
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Reichenbach P., Giordano Attianese GMP, Ouchen K., Cribioli E., Triboulet M., Ash S., Saillard M., Vuillefroy de Silly R., Coukos G., Irving M., 2023/09. Nature biomedical engineering, 7 (9) pp. 1063-1080. Peer-reviewed.
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fierle J.K., Abram-Saliba J., Atsaves V., Brioschi M., de Tiani M., Reichenbach P., Irving M., Coukos G., Dunn S.M., 2022/01/21. Scientific reports, 12 (1) p. 1136. Peer-reviewed.
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P. et al., 2021/02/25. Journal of medicinal chemistry, 64 (4) pp. 2205-2227. Peer-reviewed.
 
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G., Gainza P., Gray-Gaillard E., Cribioli E., Shui S., Kim S., Kwak M.J., Vollers S., Corria Osorio A.J., Reichenbach P. et al., 2020/04. Nature biotechnology, 38 (4) pp. 426-432. Peer-reviewed.
 
CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8<sup>+</sup> T-cell Responses.
Liu Y., Cuendet M.A., Goffin L., Šachl R., Cebecauer M., Cariolato L., Guillaume P., Reichenbach P., Irving M., Coukos G. et al., 2019/12/06. Journal of molecular biology, 431 (24) pp. 4941-4958. Peer-reviewed.
 
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
Röhrig U.F., Majjigapu S.R., Caldelari D., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P., Zoete V. et al., 2016/09/01. Bioorganic & medicinal chemistry letters, 26 (17) pp. 4330-4333. Peer-reviewed.
Elf-1 contributes to the function of the complex interleukin (IL)-2-responsive enhancer in the mouse IL-2 receptor alpha gene.
Serdobova I., Pla M., Reichenbach P., Sperisen P., Ghysdael J., Wilson A., Freeman J., Nabholz M., 1997. Journal of Experimental Medicine, 185 (7) pp. 1211-1221.
 
Interleukins (IL)-1 and IL-2 control IL-2 receptor alpha and beta expression in immature thymocytes.
Wilson A., Corthésy P., Reichenbach P., MacDonald H.R., Nabholz M., 1994. European Journal of Immunology, 24 (8) pp. 1729-1735.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University